Want to see FR:MAAT full AI Analyst Report?
MaaT Pharma (MAAT) Income Statement
MaaT Pharma Income Statement
Last quarter (Q2 2026), MaaT Pharma's total revenue was $1.08M, a decrease of 37.30% from the same quarter last year. In Q2, MaaT Pharma's net income was $-18.33M. See MaaT Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.52M | $ 3.22M | $ 2.23M | $ 1.43M | $ 972.00K | |
| $ 1.39M | $ 1.97M | $ 784.00K | $ 1.09M | $ 806.00K | |
| $ 35.54M | $ 30.39M | $ 25.39M | $ 14.65M | $ 9.70M | |
| Depreciation and Amortization | $ 1.74M | $ 1.69M | $ 871.00K | $ 429.00K | $ 328.00K |
| $ -32.41M | $ -26.34M | $ -22.07M | $ -13.10M | $ -8.57M | |
| $ -34.15M | $ -28.43M | $ -19.94M | $ -13.56M | $ -8.89M | |
| $ -705.00K | $ -3.99M | $ 226.00K | $ -156.00K | $ -126.00K | |
| $ -34.85M | $ -32.42M | $ -19.72M | $ -13.71M | $ -9.02M | |
| $ -31.06M | $ -28.90M | $ -19.72M | $ -13.71M | $ -9.02M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.95 | $ -2.20 | $ -1.73 | $ -1.39 | $ -3.72 |
| Diluted EPS | $ -1.95 | $ -2.20 | $ -1.73 | $ -1.39 | $ -3.72 |
| Weighted Average Shares Outstanding | 15.93M | 13.06M | 11.37M | 9.89M | 2.43M |
| Weighted Average Shares Outstanding (Diluted) | 15.93M | 13.06M | 11.37M | 9.89M | 2.43M |
Currency in EUR